InflaRx N.V. | CIK:0001708688 | 3

  • Filed: 3/29/2018
  • Entity registrant name: InflaRx N.V. (CIK: 0001708688)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1708688/000095010318003977/0000950103-18-003977-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1708688/000095010318003977/ifrx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001708688
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants

    The Group receives certain government grants that support its research efforts in defined projects. These grants generally provide for reimbursement of approved costs incurred as defined in the respective grants. Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured. Government grants relating to costs are deferred and recognized in the consolidated statement of comprehensive loss over the period to match them with the costs they are intended to compensate.

     

    Government grants whose primary condition is that the Group purchase non-current assets are recognized as deferred income in the consolidated statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets.

     

    When the cash in relation to recognized government grants is not yet received, the amount is included as a receivable on the statement of financial position.

     

    The Group recognizes income from government grants under ‘other income and expenses (net)’ in the consolidated statement other comprehensive loss.